Oncomed S.R.L.
- Address
- lock Available on a paid plan
Oncology
The Oncomed S.R.L. research site in Timisoara focuses on neoplasms, conducting a broad portfolio of studies across solid tumors. Trials aim to test new therapies, improve existing treatment regimens, and explore predictive biomarkers in cancers such as breast, lung, prostate, bladder, melanoma, and cutaneous squamous cell carcinoma. The overarching goal is to enhance patient outcomes by evaluating effectiveness, safety, and durability of innovative drug combinations and targeted agents.
- Hormone‑responsive breast cancer therapies
- KRAS‑mutated non‑small cell lung cancer strategies
- Immunotherapy‑based regimens for melanoma and cSCC
- Combination chemo‑radiotherapy for muscle‑invasive bladder cancer
- Targeted maintenance approaches in endometrial cancer
- Androgen‑deprivation strategies for metastatic prostate cancer
- PARP‑inhibitor plus checkpoint inhibitor studies in HRR‑deficient tumors
- Novel subcutaneous formulation comparisons for pembrolizumab
- Advanced cutaneous squamous cell carcinoma safety assessments
- Evaluation of endocrine therapy extensions to prevent recurrence
With 20 active clinical trials led by 20 investigators, Oncomed S.R.L. operates as a commercial laboratory and research facility, contributing valuable data to the European oncology community.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 10 therapeutic areas and 15 of 152 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 151 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 22 by active trials.
- 1Merck Sharp & Dohme LLC7active
lock +21 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC20trials
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Oncomed S.R.L.
lock Showing 1 of 89 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 152 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 39 | Unknown | 2018-08-24 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.